Erlotinib in the treatment of advanced pancreatic cancer

References

• Abou-AlfaGKLetourneauRHarkerG2006Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol244441716983112
   PubMed Web of Science ®Google Scholar
• ArteagaC2001The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaJ Clin Oncol1918s32s40s11560969
   PubMed Web of Science ®Google Scholar
• BellDWLynchTJHaserlatSM2005Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trialsJ Clin Oncol2380819216204011
   PubMed Web of Science ®Google Scholar
• BerlinJDCatalanoPThomasJP2002Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297J Clin Oncol203270512149301
   PubMed Web of Science ®Google Scholar
• BlaszkowskyLSKulkeKHRyanKP2005A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancerJ Clin Oncol2316S abstract 4099
   PubMedGoogle Scholar
• BloomstonMBhardwajAEllisonE2006Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray techniqueDig Surg2374916717472
   PubMed Web of Science ®Google Scholar
• BrunsCJSolorzanoCCHarbisonMT2000Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinomaCancer Res6029263410850439
   PubMed Web of Science ®Google Scholar
• BurrisHAMooreMJAndersenJ1997Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol152403139196156
   PubMed Web of Science ®Google Scholar
• CappuzzoFHirschFRRossiE2005Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerJ Nat Cancer Inst976435515870435
   PubMed Web of Science ®Google Scholar
• CappuzzoFLigorioCJannePA2007Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialJ Clin Oncol2522485517538169
   PubMed Web of Science ®Google Scholar
• ChungKYShiaJKemenyN2005Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor by immunohistochemistryJ Clin Oncol2318031015677699
   PubMed Web of Science ®Google Scholar
• CohenuramMSaifM2007Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present, and the futureJ Pancreas8415
   PubMedGoogle Scholar
• CunninghamDChauIStockenD2005Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerECCO 13 European Cancer Conference abstract PS11
   Google Scholar
• DentPReardonDBParkJS1999Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell deathMol Biol Cell10249350610436007
   PubMed Web of Science ®Google Scholar
• DragovichTHubermanMvon HoffDD2007Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trialCancer Chemother Pharmacol6029530317149608
   PubMed Web of Science ®Google Scholar
• DuffyAKortmanskyJSchwartzGK2008A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinomaAnn Oncol19869117878176
   PubMed Web of Science ®Google Scholar
• DurkinAJOsborneDAYeatmanTJ2006EGF receptor antagonism improves survival in a murine model of pancreatic carcinomaJ Surg Res13519520116678855
   PubMed Web of Science ®Google Scholar
• EberhardDAJohnsonBEAmlerLC2005Predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol235900916043828
   PubMed Web of Science ®Google Scholar
• EpelbaumRSchnaiderJGluzmanA2007Erlotinib as a single-agent therapy in patients with advanced pancreatic cancerASCO Gastrointestinal Cancers Symposium abstract 202
   Google Scholar
• GatzemeierUPluzanskaASzczesnaA2007Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trialJ Clin Oncol2515455217442998
   PubMed Web of Science ®Google Scholar
• Gomez-MartinCCamaraJCCortesH2007A phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancerJ Clin Oncol2518s abstract 4611
   Google Scholar
• GrandisJRSokJC2004Signaling through the epidermal growth factor receptor during the development of malignancyPharmacol Ther102374615056497
   PubMed Web of Science ®Google Scholar
• GridelliCMaionePAmorosoD2007Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel MeetingCrit Rev OncIn press
   Google Scholar
• GrunwaldVHidalgoM2003Developing inhibitors of the epidermal growth factor receptor for cancer treatmentJ Nat Cancer Inst958516712813169
   PubMed Web of Science ®Google Scholar
• HeinemannVHinkeABöckSGemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trialsJ Clin Oncol2518s abstract 4515
   Google Scholar
• HeinemannVLabiancaRHinkeALouvetC2007Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter studyAnn Oncol18101652917660491
   PubMed Web of Science ®Google Scholar
• HerrmannRBodokyGRuhstallerT2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJ Clin Oncol252212717538165
   PubMed Web of Science ®Google Scholar
• HidalgoMSiuLNemunaitisJ2001Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol1932677911432895
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMCappuzzoF2007Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibAnnals of Oncology187526017317677
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMMcCoyJ2005Increased epidermal growth factor recptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group StudyJ Clin Oncol2368384515998906
   PubMed Web of Science ®Google Scholar
• HuangSMBockJMHarariPM1999Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of head and neckCancer Res5919354010213503
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardE2007Cancer statistics 2007CA Cancer J Clin57436617237035
   PubMed Web of Science ®Google Scholar
• KindlerHLBylowKAHochsterHS2006A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysisJ Clin Oncol2418s abstract 4040
   Google Scholar
• KoAHDitoESchillingerB2007A phase II trial of bevacizumab plus erlotinib for patients with metastatic gemcitabine-refractory pancreatic cancerASCO Gastrointestinal Cancers Symposium abstract 187
   Google Scholar
• KolbAKeelfJArnoldN2006Expression and differential signaling of heregulins in pancreatic cancer cellsInt J Cancer1205142317096356
   PubMed Web of Science ®Google Scholar
• KrishnanSBrownPDBallmanKV2006Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177Int J Radiat Oncol Biol Phys651192916626884
   PubMed Web of Science ®Google Scholar
• KwakELJankowskiJThayerSP2006Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adeno-carcinomasClin Cancer Res124283716857803
   PubMed Web of Science ®Google Scholar
• LammeringGValerieKLinPS2001Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptorClin Cancer Res76829011297265
   PubMed Web of Science ®Google Scholar
• LeeJJangKTKiCS2007Impact of epidermal growth factor receptor (EFGR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinomaCancer1091561917354229
   PubMed Web of Science ®Google Scholar
• LenzH-JVan CutsemEKhambata-FordS2006Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesJ Clin Oncol2449142117050875
   PubMed Web of Science ®Google Scholar
• LiJKleefJGieseN2004Gefitinib (Iressa, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formationInt J Oncol252031015202007
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelP2005Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol2335091615908661
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaR2004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021293915118073
   PubMed Web of Science ®Google Scholar
• MarshallJ2006Clinical implications of the mechanism of epidermal growth factor receptor inhibitorsCancer10712071816909423
   PubMed Web of Science ®Google Scholar
• MendelsohnJBaselgaJ2003Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol212787279912860957
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJ2005Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)J Clin Oncol2316s abstract 1
   Google Scholar
• MooreMJda Cunha SantosGKamel-ReidS2007aThe relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3J Clin Oncol2518S abstract 4521
   Google Scholar
• MooreMJGoldsteinDHammJ2007bErlotinib plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol251960617452677
   PubMed Web of Science ®Google Scholar
• MoyerJDBarbacciEGIwataKK1997Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res574838489354447
   PubMed Web of Science ®Google Scholar
• MurphyLOCluckMWLovasS2001Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditionsBrit J Cancer8492693511286473
   PubMed Web of Science ®Google Scholar
• NgSSTsaoMSNickleeT2002Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinomaMol Cancer Ther17778312492110
   PubMed Web of Science ®Google Scholar
• OettleHPostSNeuhausPGellertK2007Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancerJAMA2972677717227978
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJC2004EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience304149750015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVA2005Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directionsJ Clin Oncol2325566815767641
   PubMed Web of Science ®Google Scholar
• Perez-SolerRSaltzL2005Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?J Clin Oncol2352354616051966
   PubMed Web of Science ®Google Scholar
• PhilipPABenedettiJFenoglio-PreiserC2007Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 studyJ Clin Oncol2518s abstract LBA4509
   PubMedGoogle Scholar
• PollackVASavageDMBakerDA1999Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther2917394810525095
   PubMed Web of Science ®Google Scholar
• PorterfieldBWDragovichTPatnaikAErlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trialJ Clin Oncol2214S abstract 4110
   PubMedGoogle Scholar
• Rocha LimaCMGreenMRRotcheR2004Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol2237768315365074
   PubMed Web of Science ®Google Scholar
• Schmidt-UllrichRKMikkelsenRBDentP1997Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylationOncogene15119179294612
   PubMed Web of Science ®Google Scholar
• SegaertSVan CutsemE2005Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnn Oncol1614253316012181
   PubMed Web of Science ®Google Scholar
• ShepherdFATsaoMS2006Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapyJ Clin Oncol2412192016505443
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEE2004Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrpsine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol22778514701768
   PubMed Web of Science ®Google Scholar
• TakanoTOheYSakamotoH2005Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancerJ Clin Oncol2368293715998907
   PubMed Web of Science ®Google Scholar
• TejparSPeetersMHumbletY2007Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD), and efficacy dataJ Clin Oncol2518s abstract 4037
   Google Scholar
• TobitaKKijimaHDowakiS2003Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasesInt J Mol Med11305912579331
   PubMed Web of Science ®Google Scholar
• TzengCWFrolovAFrolovaN2007Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancerSurgery141464917383523
   PubMed Web of Science ®Google Scholar
• TzengCWFrolovAFrolovaN2007Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib responseAnn Surg Onc1421508
   PubMed Web of Science ®Google Scholar
• UedaSOgataSTsudaH2004The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness; poor prognosis in patients with pancreatic ductal adenocarcinomaPancreas29e1815211117
   PubMed Web of Science ®Google Scholar
• WackerBNagraniTWeinbergJ2007Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studiesClin Cancer Res1339132117606725
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiM2001Untangling the ErbB signaling networkNat Rev Mol Cell Biol21273711252954
   PubMed Web of Science ®Google Scholar
• YipDKarapetisCStricklandA2006Chemotherapy and radio-therapy for inoperable advanced pancreatic cancerCochrane Database Syst Rev3CD00209316855985
   PubMedGoogle Scholar
• YamanakaYFriessHKobrinMS1993Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressivenessAnticancer Res1356598317885
   PubMed Web of Science ®Google Scholar